Earnings Share on Facebook Share on Twitter Share on Pinterest Share on LinkedIn J&J's pharmaceutical division is humming along, and the MedTech problems should be temporary. Read the original report. Share on Facebook Share on Twitter Share on Pinterest Share on LinkedIn Articles You May Like After a yearslong slump, China’s real estate market may be set for a turnaround Samsung forecasts record third-quarter profit of $80 billion as AI boom fuels chip demand Modelo owner Constellation is getting creative to bring back beer drinkers as overall demand weakens CNBC’s No. 1 financial advisor takes a family-office approach: ‘There is real value in all of those relationships’ Trump Accounts top 70 million as new stock-donation rules open door to ‘mega donors,’ official says